Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma

Solino, Gabriela Azevedo; Ferreira, Raphael Paiva Cock; D’Albuquerque, Luiz Augusto Carneiro; Farias, Alberto Queiróz; Trindade, Lí­via Zardo; Vasconcelos, Vitor Fiorin de; Pacheco, Mariana Poltronieri

doi:10.53855/bjt.v26i1.444_eng

Cited by 2 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have collated data from all reported patients who received checkpoint inhibitors just before liver transplantation for HCC (Table 3). These include 4 case series [79][80][81][82] and various single case reports [83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99]. Altogether, rejection occurred in 8 out of 41 patients, in which there were 2 deaths[89,95] and 1 requiring re-transplant [81,83].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…Red: patients who died from rejection. Green: data from Chouik et al, 98 Solino et al, 88 and Sogbe et al, 85 where the exact washout period was not reported.…”

Section: Author and Yearmentioning

confidence: 99%

“…These include four case-series [79][80][81][82] and various single case reports. [83][84][85][86][87][88][89][90][91][92][93][94][95][96][97][98][99] Altogether, rejection occurred in 8 out of 41 patients, in which there were 2 deaths 89,95 and 1 required retransplant. 81,83 It is proposed that the time between the last immune checkpoint inhibitor application and a liver transplant may influence the likelihood of rejection.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 2 more Smart Citations

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Liu,

Sethi,

et al. 2024

Semin Liver Dis

View full text Add to dashboard Cite

Liver transplantation (LT) is a highly effective treatment for carefully selected patients with hepatocellular carcinoma (HCC). In this review, we explored the development of LT selection criteria and organ allocation policies, comparing original data to underscore their historical progression into the intricate task of quantitatively estimating pre- and post-LT survivals. We emphasized the role of biomarkers such as serum AFP, DCP, circulating tumor cells, and circulating tumor DNA in predicting patient outcomes. Additionally, we examined the transplant-associated survival benefits and the difficulties in accurately calculating these benefits. We also reviewed recent advancements in targeted therapy and checkpoint inhibitors for advanced, inoperable HCC and projected their integration into liver transplantation for HCC. We further discussed the growing use of living donor liver transplants in the United States and compared its outcomes with those of deceased donor liver transplants. Furthermore, we examined the progress in machine perfusion techniques, which have shown potential in improving patient outcomes and enlarging the donor pool. These advancements present opportunities to enhance LT patient survivals, refine selection criteria, establish new priority metrics, develop innovative bridging and downstaging strategies, and formulate redesigned LT strategies for HCC treatments.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…Red: patients who died from rejection. Green: data from Chouik et al, 98 Solino et al, 88 and Sogbe et al, 85 where the exact washout period was not reported.…”

Section: Author and Yearmentioning

confidence: 99%

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Liu,

Sethi,

et al. 2024

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

Immunotherapy Prior to a Liver Transplant: Literature Review and a Case Report of Hepatocellular Carcinoma With BRCA1 Mutation

Kostrygin,

Chumachenko

2024

Innovacionnaâ medicina Kubani

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality worldwide. The effectiveness of its standard treatment in some cases remains poor.We report a case of a patient with Barcelona Clinic Liver Cancer stage C cryptogenic HCC whose life duration was 26 months after diagnosis.A 46-year-old woman, a former smoker, presented with elevated alpha-fetoprotein and a left liver lobe mass diagnosed as HCC. Pulmonary nodules (presumably metastatic) were previously found and remained stable. The left lobe of the liver was resected. Intrahepatic recurrence developed 1.5 months later. Lenvatinib+pembrolizumab therapy was prescribed and later switched to olaparib following the detection of somatic and germline BRCA1 mutation. The patient underwent a liver transplant and was prescribed a combination of tacrolimus and everolimus, later supplemented with extracorporeal photopheresis. Pulmonary nodules that were found to be metastases were treated with radiation therapy. A lethal outcome occurred 21.3 months after the transplant.The first literature review related to this case report discusses the problem of neoadjuvant immune checkpoint inhibitor therapy prior to a liver transplant. More than 100 patients have been described in 40 articles and 113 patients, in 2 multicenter studies. Although 16.7%-27.7% of patients developed rejection, such approach may be effective in downstaging the disease.

show abstract

Atezolizumab plus Bevacizumab as a Bridge for Liver Transplant in Hepatocellular Carcinoma

Cited by 2 publications

References 24 publications

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Immunotherapy Prior to a Liver Transplant: Literature Review and a Case Report of Hepatocellular Carcinoma With BRCA1 Mutation

Contact Info

Product

Resources

About